Regeneron extends BARDA deal for Inmazeb Ebola treatment supply

what happened

Regeneron Pharmaceuticals said it has extended its agreement with the US Biomedical Advanced Research and Development Authority (BARDA). Under the expanded contract, the company will deliver additional doses of Inmazeb to the US government through 2031 and expects about $270 million in payments. The deal builds on a 2020 contract with the agency.

The US Food and Drug Administration approved Inmazeb in 2020 for infections caused by Zaire ebolavirus. Regeneron is also testing its experimental therapy maftivimab against the Bundibugyo strain behind the current outbreak, which has no approved specific antiviral or licensed vaccine. Testing is taking place in the ongoing PARTNERS trial.

why it matters

The contract is modest for a company of Regeneron's size, so its direct effect on the stock is likely limited. The wider focus is the outbreak, which the source reports has infected nearly 10,000 people, killed more than 4,800 in Congo and spread to four countries. That keeps attention on companies working on Ebola countermeasures.

market impact

Regeneron: $270 mn BARDA contract adds modest revenue support; limited effect on the wider sector

tags

instruments